Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CCRL2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery (GPCR) | CCRL2 Lentivirus Premade Particles Full-length ORF for stable cell line development. Preserves native 7-TM conformation. Sequence Verified. |
View CCRL2 Products |
| Benchmark Ab | Anti-CCRL2 Recombinant Antibody Recombinant positive control for flow cytometry and binding assays. Sequence Verified. High Purity (>95%). |
View CCRL2 Products |
| Validator | CCRL2 siRNA Set For knockdown verification in functional validation assays. |
View CCRL2 Products |
| Related Target A | CMKLR1 (Chemokine-Like Receptor 1) The primary signaling receptor for chemerin; works in tandem with CCRL2-mediated ligand presentation. |
View CMKLR1 Products |
| Related Target B | RARRES2 (Chemerin) The shared functional ligand. High purity (>95%), Endotoxin Controlled, HEK293 Expressed (Native Glycosylation). |
View RARRES2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Integrity of 7-TM GPCR | Lentivirus-mediated stable cell line expression to preserve native transmembrane folding and lipid bilayer integration. |
| Non-signaling Decoy Assessment | Sequence Verified ORF clones to accurately evaluate ligand presentation (chemerin) without G-protein signaling artifacts. |
| Lack of Validated Controls | Recombinant Benchmark Antibodies included for binding and flow cytometry validation. |
| Off-Target Cross-Reactivity | Ortholog and subfamily targets (other atypical chemokine receptors) available for counter-screening. |
Live CCRL2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CCRL2 therapeutics is intensifying, with major players shifting focus from traditional chemokine blockade to microenvironmental immune modulation. As an atypical chemokine receptor (ACKR), CCRL2 does not trigger classical G-protein signaling but acts as a critical hub for presenting chemerin (RARRES2) to CMKLR1-positive cells. The next wave of R&D is targeting CCRL2 to modulate leukocyte homing, NK cell recruitment, and macrophage polarization in solid tumors and inflammatory conditions.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | Academic Institutes, Biotech Consortia | Inflammatory Arthritis, Solid Tumors (GBM, Breast) | Cell-surface binding assays (Need Lentivirus-driven stable cell lines for native conformation) |
| Small Molecule Modulators | Preclinical Discovery Programs | Neuropathic Pain, Inflammatory Diseases | Ligand competition assays (Need high-purity, HEK293-expressed RARRES2/Chemerin) |
| Combination Therapies (Anti-PD-1) | Immuno-oncology Innovators | Refractory Microenvironments | In vitro validation of NK/DC recruitment (Need stable target expression and functional validation) |